Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Thermo Fisher Scientific Inc.

Product Revenues

Product Revenues %Chg

Product Revenues Common Size

Service Revenues

Service Revenues %Chg

Service Revenues Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Cost of Product Revenues

Cost of Product Revenues %Chg

Cost of Product Revenues Common Size

Cost of Service Revenues

Cost of Service Revenues %Chg

Cost of Service Revenues Common Size

Selling, General and Administrative Expenses

Selling, General and Administrative Expenses %Chg

Selling, General and Administrative Expenses Common Size

Research and Development Expenses

Research and Development Expenses %Chg

Research and Development Expenses Common Size

Restructuring and Other Costs

Restructuring and Other Costs %Chg

Restructuring and Other Costs Common Size

Total Costs and Operating Expenses

Total Costs and Operating Expenses %Chg

Total Costs and Operating Expenses Common Size

Operating Income

Operating Income %Chg

Operating Income Common Size

Interest Income

Interest Income %Chg

Interest Income Common Size

Interest Expense

Interest Expense %Chg

Interest Expense Common Size

Other Expense, Net

Other Expense, Net %Chg

Other Expense, Net Common Size

Other Income

Other Income %Chg

Other Income Common Size

Income Before Income Taxes

Income Before Income Taxes %Chg

Income Before Income Taxes Common Size

Benefit from Income Taxes

Benefit from Income Taxes %Chg

Benefit from Income Taxes Common Size

Income from Continuing Operations

Income from Continuing Operations %Chg

Income from Continuing Operations Common Size

Loss from Discontinued Operations

Loss from Discontinued Operations %Chg

Loss from Discontinued Operations Common Size

Equity in Earnings of Unconsolidated Entities

Equity in Earnings of Unconsolidated Entities %Chg

Equity in Earnings of Unconsolidated Entities Common Size

Net Income

Net Income %Chg

Net Income Common Size

Less: Net Income Attributable to Noncontrolling Interests and Redeemable Noncontrolling Interest

Less: Net Income Attributable to Noncontrolling Interests and Redeemable Noncontrolling Interest %Chg

Less: Net Income Attributable to Noncontrolling Interests and Redeemable Noncontrolling Interest Common Size

Net Income Attributable to Thermo Fisher Scientific Inc.

Net Income Attributable to Thermo Fisher Scientific Inc. %Chg

Net Income Attributable to Thermo Fisher Scientific Inc. Common Size

Basic

Basic %Chg

Basic Common Size

Diluted

Diluted %Chg

Diluted Common Size

Cash Dividends Declared per Common Share

Cash Dividends Declared per Common Share %Chg

Cash Dividends Declared per Common Share Common Size

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Other Operating Expenses

Other Operating Expenses %Chg

Other Operating Expenses Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Interest and Investment Income

Interest and Investment Income %Chg

Interest and Investment Income Common Size

Non-Operating Income

Non-Operating Income %Chg

Non-Operating Income Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Consolidated Net Income

Consolidated Net Income %Chg

Consolidated Net Income Common Size

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	Jun '25	Dec '24	Jun '24	Dec '23	Jul '23	Dec '22
Total Revenues	21,219	21,993	20,886	21,460	21,397	22,127
Total Revenues %Chg	1.6%	2.5%	-2.4%	-3%	-6.1%	10.5%
Product Revenues
Service Revenues
Cost of Sales	12,576	12,843	12,334	12,751	13,006	13,219
Cost of Product Revenues
Cost of Service Revenues
Gross Profit	8,643	9,150	8,552	8,709	8,391	8,908
Gross Profit Margin	40.7%	41.6%	40.9%	40.6%	39.2%	40.3%
Selling, General & Administrative Expenses	4,218	4,302	4,293	4,181	4,264	4,507
Selling, General and Administrative Expenses
Research & Development Expenses	695	720	670	646	691	742
Research and Development Expenses
Other Operating Expenses	180	273	106	164	295	88
Restructuring and Other Costs
Operating Profit	3,551	3,854	3,483	3,718	3,141	3,571
Operating Income
Operating Margin	16.7%	17.5%	16.7%	17.3%	14.7%	16.1%
Interest and Investment Income	489	523	513	537	283	116
Interest Income
Equity in Earnings of Unconsolidated Entities
Interest Expense	-707	-673	-717	-749	-626	-442
Interest Expense
Non-Operating Income	-16	-2	14	-19	-46	31
Other Expense, Net
Other Income
Total Non-Operating Income	-234	-152	-190	-231	-389	-295
Income Before Provision for Income Taxes	3,317	3,702	3,293	3,487	2,752	3,276
Income Before Income Taxes
Equity in Earnings of Unconsolidated Entities
Provision for Income Taxes	187	249	408	186	98	204
Benefit from Income Taxes
Consolidated Net Income	3,130	3,453	2,885	3,301	2,654	3,072
Income from Continuing Operations
Net Income
Net Income Attributable to Minority Interests and Other	6	-6	9	-44	4	1
Less: Net Income Attributable to Noncontrolling Interests and Redeemable Noncontrolling Interest
Net Income Attributable to Discontinued Operations	—	—	—	—	—	—
Loss from Discontinued Operations
Net Income Attributable to Common Shareholders	3,124	3,460	2,875	3,345	2,650	3,071
Net Income Attributable to Thermo Fisher Scientific Inc.
Basic EPS	8.3	9	7.5	8.7	6.9	7.9
Diluted EPS	8.3	9	7.5	8.6	6.8	7.8
Basic Weighted Average Shares Outstanding	378	382	382	386	386	392
Total Shares Outstanding	377.6	380.8	382	386.6	385.9	389
Diluted Weighted Average Shares Outstanding	378	383	383	388	388	394
EBITDA	4,942	5,335	5,110	5,410	4,855	5,257
Effective Tax Rate	5.6%	6.7%	12.4%	5.3%	3.6%	6.2%